Infliximab-Induced Acute Liver Failure in a Patient With Crohn's Disease Requiring Orthotopic Liver Transplantation

Alikhan, Muhammed Mustafa; Mansoor, Emad; Satyavada, Sagarika; Greer, Katarina B.; Wei, Xin; Cohen, Stanley M.; Cooper, Gregory S.; Katz, Jeffry

doi:10.14309/crj.0000000000000586

Cited by 7 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Laboratory tests and liver biopsy made it possible to diagnose infliximab-related AIH. In this specific case, the patient experienced a progressive deterioration of her clinical conditions which made an orthotopic liver transplant necessary [49].…”

Section: Biologic Therapiesmentioning

confidence: 94%

Inflammatory Bowel Disease Therapies and Acute Liver Injury

Catanzaro,

Marotta,

Yazdani

et al. 2024

Preprint

View full text Add to dashboard Cite

Drug-induced liver disease represents one of the main problems in the therapeutic field. As with most pathologies, also in this case various risk factors can be recognised, such as age, sex, but also the gut microbiota. Therefore all drugs on the market can, in fact, cause hepatotoxicity of varying degrees. Drugs used in the treatment of IBD can also cause these adverse effects and even lead to DILI. In this review, the various classes of drugs used in the treatment of IBD were taken into consideration and the various adverse effects on the liver were illustrated. In particular, a major role has emerged regarding hepatotoxicity of immunosuppressants. Biological drugs, however, seem to be responsible for these complications to a much lesser extent.

show abstract

Section: Biologic Therapiesmentioning

confidence: 94%

Inflammatory Bowel Disease Therapies and Acute Liver Injury

Catanzaro,

Marotta,

Yazdani

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Laboratory tests and liver biopsy made it possible to diagnose infliximab-related AIH. In this specific case, the patient experienced a progressive deterioration of her clinical conditions, which made an orthotopic liver transplant necessary [ 60 ].…”

Section: Biologic Therapiesmentioning

confidence: 99%

Inflammatory Bowel Disease Therapies and Acute Liver Injury

Catanzaro,

Marotta,

Yazdani

et al. 2024

Toxics

View full text Add to dashboard Cite

Drug-induced liver disease (DILI) represents one of the main problems in the therapeutic field. There are several non-modifiable risk factors, such as age and sex, and all drugs can cause hepatotoxicity of varying degrees, including those for the treatment of inflammatory bowel diseases (IBD). The aim of this review is to illustrate the adverse effects on the liver of the various drugs used in the treatment of IBD, highlighting which drugs are safest to use based on current knowledge. The mechanism by which drugs cause hepatotoxicity is not fully understood. A possible cause is represented by the formation of toxic metabolites, which in some patients may be increased due to alterations in the enzymatic apparatus involved in drug metabolism. Various studies have shown that the drugs that can most frequently cause hepatotoxicity are immunosuppressants, while mesalazine and biological drugs are, for the most part, less associated with such complications. Therefore, it is possible to assume that in the future, biological therapies could become the first line for the treatment of IBD.

show abstract

Scavenging ROS to Alleviate Acute Liver Injury by ZnO‐NiO@COOH

Liu

Zhu

et al. 2022

Advanced Science

View full text Add to dashboard Cite

Currently, the incidence of acute liver injury (ALI) is increasing year by year, and infection with coronavirus disease 2019 (COVID-19) can also induce ALI, but there are still no targeted therapeutic drugs. ZnO-NiO particles is mainly used to clean up reactive oxygen species (ROS) in industrial wastewater, and it is insoluble in water. Its excellent properties are discovered and improved by adding shuttle-based bonds to make it more water-soluble. ZnO-NiO@COOH particles are synthetically applied to treat ALI. The p-n junction in ZnO-NiO@COOH increases the surface area and active sites, thereby creating large numbers of oxygen vacancies, which can quickly adsorb ROS. The content in tissues and serum levels of L-glutathione (GSH) and the GSH/oxidized GSH ratio are measured to assess the capacity of ZnO-NiO@COOH particles to absorb ROS. The ZnO-NiO@COOH particles significantly reduce the expression levels of inflammatory factors (i.e., IL-1, IL-6, and TNF-𝜶), macrophage infiltration, and granulocyte activation. ZnO-NiO@COOH rapidly adsorb ROS in a short period of time to block the generation of inflammatory storms and gain time for the follow-up treatment of ALI, which has important clinical significance.

show abstract

Infliximab-Induced Acute Liver Failure in a Patient With Crohn's Disease Requiring Orthotopic Liver Transplantation

Cited by 7 publications

References 12 publications

Inflammatory Bowel Disease Therapies and Acute Liver Injury

Inflammatory Bowel Disease Therapies and Acute Liver Injury

Inflammatory Bowel Disease Therapies and Acute Liver Injury

Scavenging ROS to Alleviate Acute Liver Injury by ZnO‐NiO@COOH

Contact Info

Product

Resources

About